Literature DB >> 24042449

The global NAFLD epidemic.

Rohit Loomba1, Arun J Sanyal.   

Abstract

NAFLD is a clinical syndrome characterized by predominant macrovesicular steatosis of the liver. The clinical and histological phenotypes of NAFLD extend from a nonalcoholic fatty liver to NASH. Although the prevalence of NAFLD is increasing globally, and it is set to become the predominant cause of chronic liver disease in many parts of the world, the epidemiology and demographic characteristics of NAFLD vary worldwide. Indeed, the condition is associated with obesity and insulin resistance in most cases in the Western world, but the disease manifests at a lower BMI in Asian countries and many patients do not seem to have insulin resistance as determined using conventional methods. The similarities and differences in the epidemiology of NAFLD in different regions of the world are discussed and the potential role of genetics and insulin resistance in disease progression is also presented.

Entities:  

Mesh:

Year:  2013        PMID: 24042449     DOI: 10.1038/nrgastro.2013.171

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  52 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

2.  Non alcoholic fatty liver disease.

Authors:  Nahum Méndez-Sánchez
Journal:  Ann Hepatol       Date:  2009       Impact factor: 2.400

3.  Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines.

Authors:  Shivakumar Chitturi; Geoffrey C Farrell; Etsuko Hashimoto; Toshiji Saibara; George K K Lau; José D Sollano
Journal:  J Gastroenterol Hepatol       Date:  2007-06       Impact factor: 4.029

4.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Authors:  Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass
Journal:  Hepatology       Date:  2012-07-26       Impact factor: 17.425

5.  Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community.

Authors:  Charles Asabamaka Onyekwere; Anthonia O Ogbera; Babajide O Balogun
Journal:  Ann Hepatol       Date:  2011 Apr-Jun       Impact factor: 2.400

6.  Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors.

Authors:  Pavel Babusik; Maha Bilal; Ivan Duris
Journal:  Med Princ Pract       Date:  2011-10-20       Impact factor: 1.927

Review 7.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

8.  Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.

Authors:  Mazen Noureddin; Katherine P Yates; Ivana A Vaughn; Brent A Neuschwander-Tetri; Arun J Sanyal; Arthur McCullough; Raphael Merriman; Bilal Hameed; Edward Doo; David E Kleiner; Cynthia Behling; Rohit Loomba
Journal:  Hepatology       Date:  2013-10-02       Impact factor: 17.425

9.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  M Prashanth; H K Ganesh; M V Vima; M John; T Bandgar; Shashank R Joshi; S R Shah; P M Rathi; A S Joshi; Hemangini Thakkar; P S Menon; N S Shah
Journal:  J Assoc Physicians India       Date:  2009-03

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  597 in total

1.  The prevalence and adverse profiles of fatty liver disease among different ethnic public servants in Urumqi of Xinjiang Uygur Autonomous Region in China.

Authors:  Dan Chen; Jie Guan; Xiang Xie; Wei-Yun Zhao; Palida Abulaiti; Yu Wang; Zhi-Qin Cheng; Jing Zhang; Ying Gao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study.

Authors:  Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner
Journal:  Gastroenterology       Date:  2015-08-20       Impact factor: 22.682

Review 3.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

4.  Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.

Authors:  J Cui; B Ang; W Haufe; C Hernandez; E C Verna; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-04-15       Impact factor: 8.171

Review 5.  Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis.

Authors:  Siddharth Singh; Sudhakar K Venkatesh; Rohit Loomba; Zhen Wang; Claude Sirlin; Jun Chen; Meng Yin; Frank H Miller; Russell N Low; Tarek Hassanein; Edmund M Godfrey; Patrick Asbach; Mohammad Hassan Murad; David J Lomas; Jayant A Talwalkar; Richard L Ehman
Journal:  Eur Radiol       Date:  2015-08-28       Impact factor: 5.315

6.  Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Seema Singh; Shirin Bassirian; James Kolar; Claire Faulkner; Nikhil Sinha; Ricki Bettencourt; Naveen Gara; Mark A Valasek; Bernd Schnabl; Lisa Richards; David A Brenner; Alan F Hofmann; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2018-12-02       Impact factor: 8.171

Review 7.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

8.  How bariatric surgery affects liver volume and fat density in NAFLD patients.

Authors:  Ran B Luo; Toshiaki Suzuki; Jonathan C Hooker; Yesenia Covarrubias; Alexandra Schlein; Shanglei Liu; Jeffrey B Schwimmer; Scott B Reeder; Luke M Funk; Jacob A Greenberg; Guilherme M Campos; Bryan J Sandler; Santiago Horgan; Claude B Sirlin; Garth R Jacobsen
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

9.  Genetic control of obesity, glucose homeostasis, dyslipidemia and fatty liver in a mouse model of diet-induced metabolic syndrome.

Authors:  D S Sinasac; J D Riordan; S H Spiezio; B S Yandell; C M Croniger; J H Nadeau
Journal:  Int J Obes (Lond)       Date:  2015-09-18       Impact factor: 5.095

10.  Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

Authors:  Gabriel Tayguara Silveira Guerreiro; Larisse Longo; Mariana Alves Fonseca; Valessa Emanoele Gabriel de Souza; Mário Reis Álvares-da-Silva
Journal:  Hepatol Int       Date:  2021-03-10       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.